Susan E. Shoaf

5.1k total citations · 1 hit paper
81 papers, 3.8k citations indexed

About

Susan E. Shoaf is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Susan E. Shoaf has authored 81 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 21 papers in Molecular Biology and 16 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Susan E. Shoaf's work include Electrolyte and hormonal disorders (22 papers), Ion Transport and Channel Regulation (14 papers) and Genetic and Kidney Cyst Diseases (13 papers). Susan E. Shoaf is often cited by papers focused on Electrolyte and hormonal disorders (22 papers), Ion Transport and Channel Regulation (14 papers) and Genetic and Kidney Cyst Diseases (13 papers). Susan E. Shoaf collaborates with scholars based in United States, Germany and Spain. Susan E. Shoaf's co-authors include Mitchell B. Max, Ronald Dubner, Joanne Muir, Sue Lynch, Bruce M Smoller, Suresh Mallikaarjun, M. Linnoila, Patricia Bricmont, Robert R. Rawlings and Ben J. Roberts and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and American Journal of Psychiatry.

In The Last Decade

Susan E. Shoaf

79 papers receiving 3.6k citations

Hit Papers

Effects of Desipramine, Amitriptyline, and Fluoxetine on ... 1992 2026 2003 2014 1992 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Effects of Desipramine, Amitriptyline, and Fluoxetine on Pain in Diabetic Neuropathy
    1992 794 citations Susan E. Shoaf et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Susan E. Shoaf United States 31 799 777 638 522 441 81 3.8k
Piotr Gałecki Poland 38 795 1.0× 1.1k 1.5× 389 0.6× 612 1.2× 1.1k 2.5× 256 6.2k
Birgit Stoffel‐Wagner Germany 49 812 1.0× 1.0k 1.3× 539 0.8× 153 0.3× 533 1.2× 200 7.2k
Ru‐Band Lu Taiwan 37 591 0.7× 977 1.3× 942 1.5× 527 1.0× 1.1k 2.4× 146 5.2k
Abdulla A.‐B. Badawy United Kingdom 36 633 0.8× 1.4k 1.7× 647 1.0× 307 0.6× 665 1.5× 131 4.4k
Aline Silva de Miranda Brazil 36 523 0.7× 670 0.9× 638 1.0× 384 0.7× 480 1.1× 164 4.0k
Hiroaki Araki Japan 31 542 0.7× 1.4k 1.8× 1.6k 2.6× 497 1.0× 324 0.7× 267 4.2k
Yan Wu China 40 963 1.2× 1.9k 2.5× 1.2k 1.9× 662 1.3× 132 0.3× 170 5.5k
Jennifer C. Felger United States 42 659 0.8× 762 1.0× 431 0.7× 553 1.1× 967 2.2× 90 6.9k
Vidar M. Steen Norway 39 628 0.8× 1.3k 1.6× 349 0.5× 278 0.5× 906 2.1× 101 4.1k
Bilal Üstündağ Türkiye 40 680 0.9× 524 0.7× 175 0.3× 229 0.4× 632 1.4× 104 4.0k

Countries citing papers authored by Susan E. Shoaf

Since Specialization
Citations

This map shows the geographic impact of Susan E. Shoaf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan E. Shoaf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan E. Shoaf more than expected).

Fields of papers citing papers by Susan E. Shoaf

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan E. Shoaf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan E. Shoaf. The network helps show where Susan E. Shoaf may publish in the future.

Co-authorship network of co-authors of Susan E. Shoaf

This figure shows the co-authorship network connecting the top 25 collaborators of Susan E. Shoaf. A scholar is included among the top collaborators of Susan E. Shoaf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan E. Shoaf. Susan E. Shoaf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shoaf, Susan E., et al.. (2024). Conducting clinical trials with self-collection of pharmacokinetic samples: Experience from an exploratory, phase 1, open-label trial of centanafadine SR in healthy individuals. Contemporary Clinical Trials Communications. 43. 101396–101396. 2 indexed citations
2.
Shoaf, Susan E., et al.. (2024). At‐Home Self‐Collection of Pharmacokinetic Data: Design and Results From a Phase 1 Open‐Label Feasibility Trial. Clinical Pharmacology in Drug Development. 14(1). 11–17. 1 indexed citations
3.
Mekahli, Djalila, Lisa M. Guay‐Woodford, Laurence Greenbaum, et al.. (2023). #3034 PHASE 3 TRIAL OF TOLVAPTAN IN PEDIATRIC AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): TWO YEARS OF DATA FROM AN OPEN-LABEL EXTENSION. Nephrology Dialysis Transplantation. 38(Supplement_1).
4.
Mekahli, Djalila, Lisa M. Guay‐Woodford, Melissa A. Cadnapaphornchai, et al.. (2023). Tolvaptan for Children and Adolescents with Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology. 18(1). 36–46. 22 indexed citations
5.
Shoaf, Susan E., et al.. (2017). Low-dose tolvaptan PK/PD: comparison of patients with hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion to healthy adults. European Journal of Clinical Pharmacology. 73(11). 1399–1408. 17 indexed citations
6.
Devuyst, Olivier, Arlene B. Chapman, Susan E. Shoaf, Frank S. Czerwiec, & Jaime D. Blais. (2017). Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4. Kidney International Reports. 2(6). 1132–1140. 36 indexed citations
7.
Woodhead, Jeffrey L., William J. Brock, Sharin E. Roth, et al.. (2016). Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors. Toxicological Sciences. 155(1). 61–74. 71 indexed citations
8.
Shoaf, Susan E., Patricia Bricmont, & Suresh Mallikaarjun. (2013). Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function. Kidney International. 85(4). 953–961. 34 indexed citations
9.
Shoaf, Susan E., Suresh Mallikaarjun, & Patricia Bricmont. (2011). Effect of grapefruit juice on the pharmacokinetics of tolvaptan, a non-peptide arginine vasopressin antagonist, in healthy subjects. European Journal of Clinical Pharmacology. 68(2). 207–211. 20 indexed citations
10.
Shoaf, Susan E., et al.. (2007). Serotonergic influences on life‐history outcomes in free‐ranging male rhesus macaques. American Journal of Primatology. 69(8). 851–865. 37 indexed citations
11.
Shoaf, Susan E., Steven L. Bramer, Patricia Bricmont, & Christopher A. Zimmer. (2007). Pharmacokinetic and Pharmacodynamic Interaction Between Tolvaptan, a Non-Peptide AVP Antagonist, and Furosemide or Hydrochlorothiazide. Journal of Cardiovascular Pharmacology. 50(2). 213–222. 46 indexed citations
12.
Elman, Igor, David S. Goldstein, Caleb M. Adler, Susan E. Shoaf, & Alan Breier. (2001). Inverse relationship between plasma epinephrine and testosterone levels during acute glucoprivation in healthy men. Life Sciences. 68(16). 1889–1898. 24 indexed citations
13.
DePetrillo, Paolo B., et al.. (2000). Ondansetron modulates pharmacodynamic effects of ketamine on electrocardiographic signals in rhesus monkeys. European Journal of Pharmacology. 391(1-2). 113–119. 5 indexed citations
14.
Lindell, Stephen G., Stephen J. Suomi, Susan E. Shoaf, J. Dee Higley, & Markku Linnoila. (1999). Salivary prolactin as a marker for central serotonin turnover. Biological Psychiatry. 46(4). 568–572. 15 indexed citations
15.
Williams, Wendol, Susan E. Shoaf, D. Hommer, Robert R. Rawlings, & M. Linnoila. (1999). Effects of Acute Tryptophan Depletion on Plasma and Cerebrospinal Fluid Tryptophan and 5‐Hydroxyindoleacetic Acid in Normal Volunteers. Journal of Neurochemistry. 72(4). 1641–1647. 190 indexed citations
16.
Olsson, N., Susan E. Shoaf, & Norman Salem. (1998). The Effect of Dietary Polyunsaturated Fatty Acids and Alcohol on Neurotransmitter Levels in Rat Brain. Nutritional Neuroscience. 1(2). 133–140. 16 indexed citations
17.
18.
Hibbeln, Joseph R., John C. Umhau, Markku Linnoila, et al.. (1998). A replication study of violent and nonviolent subjects: cerebrospinal fluid metabolites of serotonin and dopamine are predicted by plasma essential fatty acids. Biological Psychiatry. 44(4). 243–249. 92 indexed citations
19.
Shoaf, Susan E. & Bernard Schmall. (1996). Pharmacokinetics of alpha-methyl-L-tryptophan in rhesus monkeys and calculation of the lumped constant for estimating the rate of serotonin synthesis.. Journal of Pharmacology and Experimental Therapeutics. 277(1). 219–224. 18 indexed citations
20.
Shoaf, Susan E., et al.. (1992). Pharmacokinetic data in the evaluation of the safety of food and color additives. Regulatory Toxicology and Pharmacology. 15(1). 62–72. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Piotr Gałecki Breakdown of academic impact, for papers by Birgit Stoffel‐Wagner Breakdown of academic impact, for papers by Ru‐Band Lu Breakdown of academic impact, for papers by Abdulla A.‐B. Badawy Breakdown of academic impact, for papers by Aline Silva de Miranda Breakdown of academic impact, for papers by Hiroaki Araki Breakdown of academic impact, for papers by Yan Wu Breakdown of academic impact, for papers by Jennifer C. Felger Breakdown of academic impact, for papers by Vidar M. Steen Breakdown of academic impact, for papers by Bilal Üstündağ
Rankless by CCL
2026